People with metabolic-associated fatty liver disease (MASLD, formerly known as NAFLD – see fact box) have an elevated risk of developing and dying from liver cancer. MASLD is now the main reason why the number of people developing liver cancer has risen so sharply. However, researchers at Karolinska Institutet now show that close relatives and partners also have an increased risk of developing liver cancer and advanced liver disease.
May benefit from early screening
The researchers based their study on the ESPRESSO cohort, which contains data on all liver biopsies taken in Sweden from 1965 up to the present. They identified almost 12,000 people with biopsy-proven MASLD. After matching each person with up to five comparators from the general population they identified first-degree relatives (parents, siblings and children) and partners for both groups. The study included nearly 250,000 first-degree relatives and 57,000 partners.
Followed for up to 50 years
Over an average follow-up period of 17.6 years, with some individuals being followed for up to 50 years, the researchers found that first-degree relatives of MASLD patients were 80 per cent more likely to develop liver cancer than the controls. However, as liver cancer is a relatively rare disease, the absolute increase in risk is much lower: 0.11 per cent over 20 years, according to the researchers.
Jonas F. Ludvigsson, professor at the Department of Medical Epidemiology and Biostatistics, Karolinska Institute
Shared lifestyle is an important factor
The researchers also found that partners of patients with MASLD were more likely to develop severe liver disease (such as cirrhosis) and to die from liver-related causes.
“Our findings confirm that there is a clear familial risk of MASLD and that a shared lifestyle is an important factor in its development,” says Dr Ebrahimi.
The study was financed by the Swiss National Science Foundation (SNSF) and Karolinska Institutet. Fahim Ebrahimi and coauthors Hannes Hagström and Jonas F. Ludvigsson have all had financial ties to various pharmaceutical companies, primarily in the form of research grants for unrelated studies and consultancy fees. (Newswise/SS)